CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executi...(ce in October; -- Phase I safet...)

October;

-- Phase I safety and efficacy results in October from an ongoing trial

evaluating oral belinostat for the treatment of advanced solid tumors

at the ACCR-NCI-EORTC International Conference;

-- Initial results from an ongoing CR011-vcMMAE Phase I/II trial in

October for the treatment of metastatic melanoma at the ACCR-NCI-EORTC

International Conference; and

-- Updated Phase II results from an ongoing trial evaluating belinostat

monotherapy for the treatment of cutaneous T-cell lymphoma (CTCL) or

peripheral T-cell lymphoma (PTCL) in the fourth quarter of 2007.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody-drug conjugate and small molecule therapeutics for the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the advancement of the Company's first product into Phase III, the timing of upcoming clinical tr
'/>"/>